Study design and baseline characteristics of the EXPAND study: Evaluation of effectiveness and safety of xa inhibitor, rivaroxaban for the prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed as non-valvular atrial fibrillation

Takanori Ikeda, Hirotsugu Atarashi, Hiroshi Inoue, Shinichiro Uchiyama, Takanari Kitazono, Takeshi Yamashita, Wataru Shimizu, Masahiro Kamouchi, Koichi Kaikita, Koji Fukuda, Hideki Origasa, Ichiro Sakuma, Keijiro Saku, Yasuo Okumura, Yuichiro Nakamura, Hideo Morimoto, Naoki Matsumoto, Akihito Tsuchida, Junya Ako, Nobuyoshi SugishitaShogo Shimizu, Hiroaki Shimokawa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The use of rivaroxaban, a factor Xa inhibitor, has been increasing for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) in Japan. We conducted the nationwide multicenter study, termed as the EXPAND Study, to address its effectiveness and safety in the real-world practice of patients with non-valvular AF in Japan. The EXPAND Study is a prospective, non-interventional, observational cohort study to evaluate the effectiveness and safety of rivaroxaban in non-valvular AF patients in a real-world clinical practice. A total of 7,178 patients with non-valvular AF were enrolled in 684 medical institutes between November 20, 2012 and June 30, 2014. As for the baseline demographic and clinical characteristics of 7,164 patients, the proportion of female patients was 32.2%, and those of patients with creatinine clearance < 50 mL/min and non-paroxysmal (persistent or permanent) AF were 21.8% and 55.1%, respectively. The proportions of patients complicated with hypertension, congestive heart failure, diabetes mellitus, and a history of ischemic stroke were 70.9%, 25.9%, 24.3%, and 20.2%, respectively. The proportions of patients with a CHADS2 score ≤ 1 and a CHA2DS2-VASc score ≤ 1 were 37.3% and 13.6%, respectively. They were followed up until March 31, 2016 for a mean follow-up period of approximately 2.5 years. The findings of the EXPAND Study will help to establish an appropriate treatment with rivaroxaban for Japanese patients with non-valvular AF.

Original languageEnglish
Pages (from-to)259-268
Number of pages10
JournalTohoku Journal of Experimental Medicine
Volume240
Issue number4
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Embolism
Atrial Fibrillation
Stroke
Safety
Medical problems
Creatinine
Japan
Rivaroxaban
Multicenter Studies
Observational Studies
Diabetes Mellitus
Cohort Studies
Heart Failure
Demography
Hypertension

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Study design and baseline characteristics of the EXPAND study : Evaluation of effectiveness and safety of xa inhibitor, rivaroxaban for the prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed as non-valvular atrial fibrillation. / Ikeda, Takanori; Atarashi, Hirotsugu; Inoue, Hiroshi; Uchiyama, Shinichiro; Kitazono, Takanari; Yamashita, Takeshi; Shimizu, Wataru; Kamouchi, Masahiro; Kaikita, Koichi; Fukuda, Koji; Origasa, Hideki; Sakuma, Ichiro; Saku, Keijiro; Okumura, Yasuo; Nakamura, Yuichiro; Morimoto, Hideo; Matsumoto, Naoki; Tsuchida, Akihito; Ako, Junya; Sugishita, Nobuyoshi; Shimizu, Shogo; Shimokawa, Hiroaki.

In: Tohoku Journal of Experimental Medicine, Vol. 240, No. 4, 01.12.2016, p. 259-268.

Research output: Contribution to journalArticle

Ikeda, T, Atarashi, H, Inoue, H, Uchiyama, S, Kitazono, T, Yamashita, T, Shimizu, W, Kamouchi, M, Kaikita, K, Fukuda, K, Origasa, H, Sakuma, I, Saku, K, Okumura, Y, Nakamura, Y, Morimoto, H, Matsumoto, N, Tsuchida, A, Ako, J, Sugishita, N, Shimizu, S & Shimokawa, H 2016, 'Study design and baseline characteristics of the EXPAND study: Evaluation of effectiveness and safety of xa inhibitor, rivaroxaban for the prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed as non-valvular atrial fibrillation', Tohoku Journal of Experimental Medicine, vol. 240, no. 4, pp. 259-268. https://doi.org/10.1620/tjem.240.259
Ikeda, Takanori ; Atarashi, Hirotsugu ; Inoue, Hiroshi ; Uchiyama, Shinichiro ; Kitazono, Takanari ; Yamashita, Takeshi ; Shimizu, Wataru ; Kamouchi, Masahiro ; Kaikita, Koichi ; Fukuda, Koji ; Origasa, Hideki ; Sakuma, Ichiro ; Saku, Keijiro ; Okumura, Yasuo ; Nakamura, Yuichiro ; Morimoto, Hideo ; Matsumoto, Naoki ; Tsuchida, Akihito ; Ako, Junya ; Sugishita, Nobuyoshi ; Shimizu, Shogo ; Shimokawa, Hiroaki. / Study design and baseline characteristics of the EXPAND study : Evaluation of effectiveness and safety of xa inhibitor, rivaroxaban for the prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed as non-valvular atrial fibrillation. In: Tohoku Journal of Experimental Medicine. 2016 ; Vol. 240, No. 4. pp. 259-268.
@article{e9fe8cd62b2340ef9572dfc3bea33db6,
title = "Study design and baseline characteristics of the EXPAND study: Evaluation of effectiveness and safety of xa inhibitor, rivaroxaban for the prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed as non-valvular atrial fibrillation",
abstract = "The use of rivaroxaban, a factor Xa inhibitor, has been increasing for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) in Japan. We conducted the nationwide multicenter study, termed as the EXPAND Study, to address its effectiveness and safety in the real-world practice of patients with non-valvular AF in Japan. The EXPAND Study is a prospective, non-interventional, observational cohort study to evaluate the effectiveness and safety of rivaroxaban in non-valvular AF patients in a real-world clinical practice. A total of 7,178 patients with non-valvular AF were enrolled in 684 medical institutes between November 20, 2012 and June 30, 2014. As for the baseline demographic and clinical characteristics of 7,164 patients, the proportion of female patients was 32.2{\%}, and those of patients with creatinine clearance < 50 mL/min and non-paroxysmal (persistent or permanent) AF were 21.8{\%} and 55.1{\%}, respectively. The proportions of patients complicated with hypertension, congestive heart failure, diabetes mellitus, and a history of ischemic stroke were 70.9{\%}, 25.9{\%}, 24.3{\%}, and 20.2{\%}, respectively. The proportions of patients with a CHADS2 score ≤ 1 and a CHA2DS2-VASc score ≤ 1 were 37.3{\%} and 13.6{\%}, respectively. They were followed up until March 31, 2016 for a mean follow-up period of approximately 2.5 years. The findings of the EXPAND Study will help to establish an appropriate treatment with rivaroxaban for Japanese patients with non-valvular AF.",
author = "Takanori Ikeda and Hirotsugu Atarashi and Hiroshi Inoue and Shinichiro Uchiyama and Takanari Kitazono and Takeshi Yamashita and Wataru Shimizu and Masahiro Kamouchi and Koichi Kaikita and Koji Fukuda and Hideki Origasa and Ichiro Sakuma and Keijiro Saku and Yasuo Okumura and Yuichiro Nakamura and Hideo Morimoto and Naoki Matsumoto and Akihito Tsuchida and Junya Ako and Nobuyoshi Sugishita and Shogo Shimizu and Hiroaki Shimokawa",
year = "2016",
month = "12",
day = "1",
doi = "10.1620/tjem.240.259",
language = "English",
volume = "240",
pages = "259--268",
journal = "Tohoku Journal of Experimental Medicine",
issn = "0040-8727",
publisher = "Tohoku University Medical Press",
number = "4",

}

TY - JOUR

T1 - Study design and baseline characteristics of the EXPAND study

T2 - Evaluation of effectiveness and safety of xa inhibitor, rivaroxaban for the prevention of stroke and systemic embolism in a nationwide cohort of Japanese patients diagnosed as non-valvular atrial fibrillation

AU - Ikeda, Takanori

AU - Atarashi, Hirotsugu

AU - Inoue, Hiroshi

AU - Uchiyama, Shinichiro

AU - Kitazono, Takanari

AU - Yamashita, Takeshi

AU - Shimizu, Wataru

AU - Kamouchi, Masahiro

AU - Kaikita, Koichi

AU - Fukuda, Koji

AU - Origasa, Hideki

AU - Sakuma, Ichiro

AU - Saku, Keijiro

AU - Okumura, Yasuo

AU - Nakamura, Yuichiro

AU - Morimoto, Hideo

AU - Matsumoto, Naoki

AU - Tsuchida, Akihito

AU - Ako, Junya

AU - Sugishita, Nobuyoshi

AU - Shimizu, Shogo

AU - Shimokawa, Hiroaki

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The use of rivaroxaban, a factor Xa inhibitor, has been increasing for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) in Japan. We conducted the nationwide multicenter study, termed as the EXPAND Study, to address its effectiveness and safety in the real-world practice of patients with non-valvular AF in Japan. The EXPAND Study is a prospective, non-interventional, observational cohort study to evaluate the effectiveness and safety of rivaroxaban in non-valvular AF patients in a real-world clinical practice. A total of 7,178 patients with non-valvular AF were enrolled in 684 medical institutes between November 20, 2012 and June 30, 2014. As for the baseline demographic and clinical characteristics of 7,164 patients, the proportion of female patients was 32.2%, and those of patients with creatinine clearance < 50 mL/min and non-paroxysmal (persistent or permanent) AF were 21.8% and 55.1%, respectively. The proportions of patients complicated with hypertension, congestive heart failure, diabetes mellitus, and a history of ischemic stroke were 70.9%, 25.9%, 24.3%, and 20.2%, respectively. The proportions of patients with a CHADS2 score ≤ 1 and a CHA2DS2-VASc score ≤ 1 were 37.3% and 13.6%, respectively. They were followed up until March 31, 2016 for a mean follow-up period of approximately 2.5 years. The findings of the EXPAND Study will help to establish an appropriate treatment with rivaroxaban for Japanese patients with non-valvular AF.

AB - The use of rivaroxaban, a factor Xa inhibitor, has been increasing for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF) in Japan. We conducted the nationwide multicenter study, termed as the EXPAND Study, to address its effectiveness and safety in the real-world practice of patients with non-valvular AF in Japan. The EXPAND Study is a prospective, non-interventional, observational cohort study to evaluate the effectiveness and safety of rivaroxaban in non-valvular AF patients in a real-world clinical practice. A total of 7,178 patients with non-valvular AF were enrolled in 684 medical institutes between November 20, 2012 and June 30, 2014. As for the baseline demographic and clinical characteristics of 7,164 patients, the proportion of female patients was 32.2%, and those of patients with creatinine clearance < 50 mL/min and non-paroxysmal (persistent or permanent) AF were 21.8% and 55.1%, respectively. The proportions of patients complicated with hypertension, congestive heart failure, diabetes mellitus, and a history of ischemic stroke were 70.9%, 25.9%, 24.3%, and 20.2%, respectively. The proportions of patients with a CHADS2 score ≤ 1 and a CHA2DS2-VASc score ≤ 1 were 37.3% and 13.6%, respectively. They were followed up until March 31, 2016 for a mean follow-up period of approximately 2.5 years. The findings of the EXPAND Study will help to establish an appropriate treatment with rivaroxaban for Japanese patients with non-valvular AF.

UR - http://www.scopus.com/inward/record.url?scp=85003486120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003486120&partnerID=8YFLogxK

U2 - 10.1620/tjem.240.259

DO - 10.1620/tjem.240.259

M3 - Article

C2 - 27904005

AN - SCOPUS:85003486120

VL - 240

SP - 259

EP - 268

JO - Tohoku Journal of Experimental Medicine

JF - Tohoku Journal of Experimental Medicine

SN - 0040-8727

IS - 4

ER -